Korea S.E.
18:00:00 2024-05-30 EDT
5-day change
1st Jan Change
35,700
KRW
+6.41%
+3.78%
+5.78%
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.
February 23, 2021 at 02:56 am
From October 1, 2020 to December 31, 2020, the company has repurchased 89,767 shares, representing 0.95% for KRW 2,146.74 million. With this, the company has completed the repurchase of 121,247 shares, representing 1.28% for KRW 2,987.19 million under the buyback announced on August 14, 2020.
Humedix Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.
05-23
CI
Humedix Co., Ltd. authorizes a Buyback Plan.
05-23
CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on September 27, 2022.
23-03-27
CI
Humedix Co., Ltd.'s Equity Buyback announced on September 27, 2022, has expired with 145,877 shares, representing 1.58% for KRW 2,992.33 million.
23-03-26
CI
Ensol Biosciences Inc. announced that it has received KRW 4.99999995 billion in funding from Humedix Co., Ltd.
23-02-19
CI
Ensol Biosciences Inc. announced that it expects to receive KRW 4.99999995 billion in funding from Humedix Co., Ltd.
23-02-09
CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on September 27, 2022.
22-12-27
CI
Humedix Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.
22-09-27
CI
Humedix Co., Ltd. authorizes a Buyback Plan.
22-09-26
CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on March 16, 2022.
22-09-16
CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on March 16, 2022.
22-09-16
CI
Humedix Co., Ltd.'s Equity Buyback announced on March 16, 2022, has expired with 136,591 shares, representing 1.46% for KRW 2,982.87 million.
22-09-15
CI
An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. for KRW 21.5 billion.
22-06-21
CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on March 16, 2022.
22-06-17
CI
Humedix Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.
22-03-15
CI
Humedix Co., Ltd. authorizes a Buyback Plan.
22-03-15
CI
Kineta, Inc. announced that it has received funding from Humedix Co., Ltd.
21-10-03
CI
Kineta, Inc. announced that it expects to receive funding from Humedix Co., Ltd.
21-09-29
CI
Huons Global : S.Korean consortium to produce 100 mln doses a month of Russia's Sputnik V vaccine
21-04-15
RE
Humedix Co., Ltd. announced that it has received KRW 45 billion in funding from a group of investors
21-04-05
CI
Humedix Co., Ltd. announced that it expects to receive KRW 45 billion in funding from a group of investors
21-04-01
CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.
21-02-23
CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.
21-02-23
CI
Humedix Co., Ltd.'s Equity Buyback announced on August 14, 2020, has expired with 121,545 shares, representing 1.28% for KRW 2,994.19 million.
21-02-17
CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.
20-11-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Humedix Co., Ltd. is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals .The Companyâs main products consist of preparations for the treatment of arthritis, prescription drugs, medicament for the eyes, active pharmaceutical ingredients (APIs), as well as cosmetics and others. The Company distributes its products within domestic market and to overseas markets
More about the company
Last Close Price
35,700
KRW
Average target price
56,000
KRW
Spread / Average Target
+56.86%
Consensus
1st Jan change
Capi.
+5.78% 268M +40.73% 739B +32.83% 598B -6.30% 353B +15.15% 318B +4.05% 285B +15.00% 240B +9.78% 210B -5.52% 206B +6.17% 164B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
HUMEDIX CO., LTD. 
